*Read Disclaimer Sponsored Content | Unsubscribe
Hello!
New Alert: EUDA Health Holdings Limited (NASDAQ: EUDA)
EUDA is our brand new NASDAQ technical-breakout alert.
In addition, just this morning the company announced breaking news that could be another catalyst for growth.
EUDA has a chart setup suggesting the potential for increased gains.
Over the past few days, EUDA has rallied more than 25% after experiencing weakness last week.
The renewed momentum could be the driving force for further upside.
EUDA has a 50 day moving average of 3.13, more than 17% from yesterday's close.
Above this level, EUDA could present increased growth potential.
EUDA has a 200 day moving average of 3.80, more than 42% above yesterday's close.
In addition, EUDA has a RSI of 46, showing the potential for increased upside.
EUDA is a NASDAQ listed "non-invasive healthcare provider in Asia".
EUDA aims to become a "market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector".
The company's "mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly".
By offering "innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care".
EUDA is based in "Singapore" with a "focus on Singapore, Malaysia, and China", in addition to running a "Singapore-based property management business".
EUDA offers a "diverse portfolio of innovative non-invasive wellness products and services, including bioenergy capsules and stem cell therapies, marketed under the CK Health brand in Malaysia and Singapore".
The company has an "Expansive holistic wellness consumer product portfolio sold under the CK Health Plus brand":
- "Bioenergy Capsules"
- "Hydrogen Cellular Therapies"
- "Collagen Drinks"
- "Therapeutic-Grade Essential Oils"
- "Anti-Aging Supplements"
In addition, the company has "37" "Stem Cell Treatment Centers operated by our partner, Guangdong Cell Biotech – Across China, Indonesia and Cambodia".
Through this partnership they are "unlocking a healthier future with a regenerative healing approach that delivers anti-aging benefits, boosts immune function, treats chronic conditions and offers tailored medical solutions".
Together, they "are building an industrial chain integrating stem cell storage and high-tech regenerative medicine centers".
Their focus is the discovery of "cutting-edge ASEL (Adult Small Embryonic-Like Stem Cells), TCEL (Immune Cell Therapy) and MSEL (Menstrual Blood-Derived Stem Cells) stem cell solutions designed for anti-aging, immune system enhancement and regenerative medicine as well as storage facilities offered by Guandong Cell Biotech in China".
As the company further explains:
- "Guangdong Cell Biotech's internationally patented technology is transforming healthcare and unlocking new possibilities for wellness and longevity.
"Their ASEL technology extracts powerful stem cells from a small amount of fat tissue, offering safe and painless treatments for anti-aging, tissue regeneration and organ repair."
Importantly:
"TCEL strengthens the body's natural defenses by using T cells to help fight cancer and chronic diseases while reducing treatment side effects."
Furthermore:
"MSEL provides a groundbreaking solution for women's health, restoring fertility, repairing ovarian damage and supporting reproductive health."
Earlier this year, the company announced:
"EUDA Partners with Authorized Distributor of Guangdong Cell Biotech to Offer Stem Cell Therapies to Customers in Singapore and Malaysia"
"SINGAPORE, April 24, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ: EUDA), a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, today announced an update to the potential strategic partnership, previously announced in December 2024, with Guangdong Cell Biotech Co. Ltd. ("Guangdong Cell Biotech"). Guangdong Cell Biotech is a prominent player in stem cell therapies and regenerative medicine in China. It develops autologous cell treatments and tailored medicines for various disorders."
"Instead of the initially contemplated joint venture, the parties have adopted a commercial distribution arrangement structure that better aligns with their respective operational models and regional market dynamics."
"On April 22, 2025, CK Health Plus Sdn Bhd ("CK Health"), a wholly-owned subsidiary of EUDA and a direct seller of holistic wellness consumer products, signed a collaboration agreement with Guangdong Key Lock Health Management Co., Ltd. ("Keylock"), an authorized distributor of Guangdong Cell Biotech. Pursuant to this collaboration agreement, CK Health will market and sell to EUDA customers in Singapore and Malaysia stem cell therapies provided by Guangdong Cell Biotech in China."
"This revised structure builds upon the original strategic intent of the parties to collaborate, giving EUDA access to Guangdong Cell Biotech's cutting-edge stem cell therapies and regenerative medicine."
""This commercial distribution structure showcases our strategy to diversify our business and revenue streams," said Mr. Alfred Lim, CEO of EUDA. "Combining our mission to expand access to holistic healthcare solutions in Southeast Asia with Guangdong Cell Biotech's established stem cell therapies, we aim to transform the health and wellness landscape in the region.""
In addition, just this morning, the company announced breaking news:
"EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement"
"SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) ("EUDA" or the "Company"), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the "Supplement") from Chemokine Pte. Ltd. ("Chemokine"), a Singapore-based biotech company focused on molecular supplements and gene modulating formulations."
This could be a big catalyst for the company:
"EUDA and its subsidiaries will market and sell the Supplement under the brand name, Euda Helixé, initially in Singapore, Malaysia, and China before expanding it to other markets in the future. The addition of the Supplement will further reinforce EUDA's wellness product portfolio as it drives the transformation of the health and wellness landscape in the region."
Importantly:
"The Supplement is an advanced formulation designed to modulate gene expression by activating beneficial genes while silencing harmful ones. Leveraging cutting-edge epigenetic technology, the Supplement enhances metabolism, boosts vitality, supports longevity, and is positioned as a foundational pillar in EUDA's growing wellness product suite."
Here are some of the company's comments:
"Mr. Alfred Lim, CEO of EUDA, commented, "Securing exclusive distribution rights for such a special product will reinforce our portfolio of wellness product offerings and further diversify our revenue streams. The Supplement positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology. With our strong regional ecosystem and distribution capabilities, we believe that it is possible to generate sales of about 500,000 bottles over the next 12 months.""
EUDA could breakout higher.
Make sure to do your own due diligence.
Sources: PR1, PR2, Website, Chart
Happy Trading!
AwesomeStocks
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
